Journal of Clinical Immunology

, Volume 33, Issue 5, pp 903–908

Reduced Bone Density in Patients with Autosomal Dominant Hyper-IgE Syndrome

  • Oded Scheuerman
  • Vered Hoffer
  • Avner Herman Cohen
  • Cristina Woellner
  • Bodo Grimbacher
  • Ben-Zion Garty
Original Research


Background and Purpose

Autosomal dominant hyper-IgE syndrome (AD-HIES) is a rare primary immunodeficiency disorder . It has been recognized as a multisystem disorder and is characterized by both immunologic and non-immunologic manifestations. Possible bone involvement in autosomal dominant HIES include fractures, scoliosis, cystic bone changes, and osteopenia. We sought to evaluate the changes in bone density in adolescents and young adults with AD-HIES, mostly with proven STAT3 mutation, followed in our institute.


We studied eight patients with AD-HIES who attended our immunology clinic. All patients underwent at least one bone mass dual-energy x-ray absorptiometry assessment (dual-energy x-ray absorptiometry scan).These findings were evaluated.


The age of the patients at the time of their first bone density scan ranged between 10 and 24 years (mean 16.1 ± 4.0 years); the duration of follow-up was 4–11 years (mean 5.8 ± 3.5 years). Four patients had a history of fractures. Mean Z score in these patients was −1.8 ± 0.7. For three patients, Z score was below −1. The other four patients had no history of fractures. Mean Z score in these patients was −0.9 ± 0.5. Only one patient in this group had a Z score below −1. Bone density was below average in all patients; mean spinal Z score was −1.6 ± 0.4. Four patients were followed through the second decade, and all showed progressive deterioration in bone density. Three were treated with alendronate sodium, with improvement in the bone scan results.


Bone density decreases considerably over time in adolescents and young adults suffering from AD- HIES. Treatment with alendronate sodium may be effective in alleviating osteopenia.


Hyper-IgE syndrome bone density osteoporosis 


  1. 1.
    Davis SD, Schaller J, Wedgwood RJ. Job’s Syndrome. Recurrent, “cold”, staphylococcal abscesses. Lancet. 1966;1:1013–5.PubMedCrossRefGoogle Scholar
  2. 2.
    Buckley R, Wray B, Belmaker E. Extreme hyperimmunoglobulinemia E and undue susceptibility to infection. Pediatrics. 1972;49:59–70.PubMedGoogle Scholar
  3. 3.
    Grimbacher B, Holland SM, Gallin JI, Greenberg F, Hill SC, Malech HL, et al. Hyper-IgE syndrome with recurrent infections – an autosomal dominant multisystem disorder. N Engl J Med. 1999;340:692–702.PubMedCrossRefGoogle Scholar
  4. 4.
    Leung DY, Geha RS. Clinical and immunologic aspects of the hyperimmunoglobulin E syndrome. Hematol Oncol Clin North Am. 1988;2:81–100.PubMedGoogle Scholar
  5. 5.
    Blum R, Geller G, Fish LA. Recurrent severe staphylococcal infections, eczematoid rash: extreme elevations of IgE, eosinophilia and different chemotactic responses in two generations. J Pediatr. 1977;90:607–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med. 2007;357:1608–19.PubMedCrossRefGoogle Scholar
  7. 7.
    Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H, Hara T, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature. 2007;448:1058–62.PubMedCrossRefGoogle Scholar
  8. 8.
    Freeman AF, Holland SM. The hyper-IgE syndromes. Immunol Allergy Clin North Am. 2008;28:277–91.PubMedCrossRefGoogle Scholar
  9. 9.
    Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, Elias KM, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature. 2008;452:773–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Borgess WG, Hensley T, Carey JC, Petrak BA, Hill HR. The face of Job. J Pediatr. 1998;133:303–5.CrossRefGoogle Scholar
  11. 11.
    Osteoporosis prevention, diagnosis and therapy. NIH consensus statement. [No authors listed] 2000;17:1–45.Google Scholar
  12. 12.
    Uziel Y, Zifman E, Hashkes PJ. Osteoporosis in children: pediatric and pediatric rheumatology perspective: a review. Pediatr Rheumatol Online J. 2009;7:16.PubMedCrossRefGoogle Scholar
  13. 13.
    Gunes AM, Can E, Saglam H, Ilçöl YO, Baytan B. Assessment of bone mineral density and risk factors in children completing treatment for acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2010;32:e102–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Samson F, Cagnard B, Leray E, Guggenbuhl P, Bridoux-Henno L, Dabadie A. Longitudinal study of bone mineral density in children after a diagnosis of Crohn’s disease. Gastroenterol Clin Biol. 2010;334:554–61.CrossRefGoogle Scholar
  15. 15.
    Gordon CM, Bachrach LK, Carpenter TO, Crabtree N, El-Hajj Fuleihan G, Kutilek S, et al. Dual energy x-ray absorptiometry interpretation and reporting in children and adolescents: the 2007 ISCD pediatric official positions. J Clin Densitom. 2008;11:43–58.PubMedCrossRefGoogle Scholar
  16. 16.
    Schimke LF, Sawalle-Belohradsky J, Roesler J, Wollenberg A, Rack A, Borte M, et al. Diagnostic approach to the hyper-IgE syndromes: Immunologic and clinical key findings to differentiate hyper-IgE syndromes from atopic dermatitis. J Allergy Clin Immunol. 2010;126:611–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Baim S, Leonard MB, Bianchi ML, Hans DB, Kalkwarf HJ, Langman CB, et al. Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Pediatric Position Development Conference. J Clin Densitorm. 2008;11:6–21.CrossRefGoogle Scholar
  18. 18.
    Bachrach LK, Sills IN. Section on Endocrinology. Clinical report – bone densitometry in children and adolescents. Pediatrics. 2011;127:189–94.PubMedCrossRefGoogle Scholar
  19. 19.
    Grimbacher B, Schäffer AA, Holland SM, Davis J, Gallin JI, Malech HL, et al. Genetic linkage of hyper-IgE syndrome to chromosome 4. Am J Hum Genet. 1999;65:735–44.PubMedCrossRefGoogle Scholar
  20. 20.
    Zhang Z, Elte T, Troiano N, Maher SE, Fu XY, Bothwell AL. Osteoporosis with increased osteoclastogenesis in hematopoietic cell-specific STAT3-deficient mice. Biochem Biophys Res Commun. 2005;328:800–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Woellner C, Gertz EM, Schäffer AA, Lagos M, Perro M, Glocker EO, et al. Mutations in STAT3 and diagnostic guidelines for hyper-IgE. J Allergy Clin Immunol. 2009;125:424–32.CrossRefGoogle Scholar
  22. 22.
    Paulson ML, Freeman AF, Holland SM. Hyper IgE syndrome: an update on clinical aspects and the role of signal transducer and activator of transcription 3. Curr Opin Allergy Clin Immunol. 2008;8:527–33.PubMedCrossRefGoogle Scholar
  23. 23.
    Shaw NJ. Management of osteoporosis in children. Eur J Endocrinol. 2008;159:533–9.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Oded Scheuerman
    • 1
  • Vered Hoffer
    • 1
  • Avner Herman Cohen
    • 1
  • Cristina Woellner
    • 2
  • Bodo Grimbacher
    • 2
  • Ben-Zion Garty
    • 1
  1. 1.Department of Pediatrics B and Kipper Institute of Allergy and Immunology, Schneider Children’s Medical Center of Israel, Sackler Faculty of MedicineTel Aviv UniversityPetach TikvaIsrael
  2. 2.Centre of Chronic ImmunodeficiencyUniversity Hospital FreiburgFreiburgGermany

Personalised recommendations